Wedbush Maintains Neutral on Biomarin Pharmaceutical, Lowers Price Target to $70
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Andreas Argyrides has maintained a Neutral rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and lowered the price target from $73 to $70.
August 01, 2023 | 3:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wedbush analyst has maintained a Neutral rating on Biomarin Pharmaceutical and lowered the price target from $73 to $70.
The news directly pertains to Biomarin Pharmaceutical as the company's stock has been maintained at a Neutral rating by Wedbush analyst. However, the price target has been lowered from $73 to $70, which might indicate a slightly less optimistic outlook for the company's stock in the short term. This could potentially impact the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100